Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have received a consensus recommendation of “Hold” from the seven brokerages that are covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $29.00.

Several research firms have commented on ATRA. Jefferies Group LLC restated a “buy” rating and issued a $30.00 target price on shares of Atara Biotherapeutics in a research report on Thursday, August 31st. Zacks Investment Research cut Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 28th. William Blair reaffirmed an “outperform” rating on shares of Atara Biotherapeutics in a report on Monday, June 26th. ValuEngine upgraded Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Finally, Canaccord Genuity reiterated a “buy” rating and set a $47.00 price objective on shares of Atara Biotherapeutics in a research report on Monday, September 11th.

In related news, EVP Christopher Haqq sold 7,604 shares of the business’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $14.75, for a total transaction of $112,159.00. Following the sale, the executive vice president now owns 362,909 shares of the company’s stock, valued at $5,352,907.75. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Isaac E. Ciechanover sold 2,800 shares of the business’s stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $16.94, for a total value of $47,432.00. Following the sale, the chief executive officer now directly owns 731,859 shares in the company, valued at approximately $12,397,691.46. The disclosure for this sale can be found here. Insiders sold 53,909 shares of company stock valued at $810,518 in the last ninety days. Corporate insiders own 16.20% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. Redmile Group LLC increased its position in shares of Atara Biotherapeutics by 2.4% during the 1st quarter. Redmile Group LLC now owns 2,734,118 shares of the biotechnology company’s stock valued at $56,186,000 after purchasing an additional 63,176 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Atara Biotherapeutics by 617.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 201,214 shares of the biotechnology company’s stock worth $4,135,000 after buying an additional 173,184 shares in the last quarter. American International Group Inc. raised its stake in shares of Atara Biotherapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock worth $294,000 after buying an additional 948 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Atara Biotherapeutics in the 1st quarter worth $132,000. Finally, EcoR1 Capital LLC raised its stake in shares of Atara Biotherapeutics by 101.5% in the 1st quarter. EcoR1 Capital LLC now owns 434,812 shares of the biotechnology company’s stock worth $8,935,000 after buying an additional 219,000 shares in the last quarter. 82.95% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Atara Biotherapeutics, Inc. (ATRA) Receives Consensus Rating of “Hold” from Analysts” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/10/04/atara-biotherapeutics-inc-atra-receives-consensus-rating-of-hold-from-analysts.html.

Shares of Atara Biotherapeutics (NASDAQ:ATRA) traded up 0.90% during trading on Wednesday, hitting $16.80. The stock had a trading volume of 67,145 shares. Atara Biotherapeutics has a one year low of $11.80 and a one year high of $23.00. The firm’s market cap is $513.39 million. The firm’s 50-day moving average is $15.13 and its 200-day moving average is $15.64.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by ($0.05). Equities research analysts forecast that Atara Biotherapeutics will post ($3.89) EPS for the current year.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.